The researchers concluded that molnupiravir has benefits for patients and the health system beyond those already known.
Extra clinical benefits from molnupiravir antiviral drug (molnupiravir) in pill form, from Merck company, found a new analysis of the findings of the randomized and placebo-controlled clinical trial MOVe-OUT. The administration of the pill leads to reduced need for respiratory interventions and to fewer cases of short-term medical care.
The pill is mainly intended for non-patients patients with mild to moderate Covid-19, but which have risk factors for deterioration and severe disease. The third phase of the MOVe-OUT clinical trial had demonstrated the safety and efficacy of the drug, which reduces the risk of hospitalization. Preliminary results also showed that those who took molnupiravir, recovered faster than most Covid-19 symptoms and they had greater reduction in their mean viral load.
See the scientific publication by clicking here.
Now, in a secondary analysis of those results, the researchers, who made the relevant publication in the American Medical Journal “Annals of Internal Medicine”, found that there are additional benefits that have not been identified to date. It was found that administration of the pill (800 mg every 12 hours for five days) to 1,433 non-hospitalized patients over 18 years of age, compared with placebo, resulted in faster biomarker recovery such as C-reactive protein (CRP), in fewer respiratory interventions and to less need for short-term care of untreated patients with coronavirus.
Inpatients who took the pill also had a reduced need for respiratory interventions and were discharged on average three days before those taking placebo. The researchers concluded that molnupiravir has benefits for patients and the health system beyond those already known.
